Interleukin-2 (IL-2) is an immune activator, which has a significant regulatory function of immune effector cells.[3] The patient was treated with high-dose IL-2 and the tumor disappeared after only a few months.[4] High dose of IL-2 (12∼24 MIU/m2) maintenance therapy can alleviate the condition of patients with advanced AML, but its adverse reactions are also very serious.[5] Pautas et al[6] compared the efficacy of IL-2 with placebo in the maintenance treatment of AML through many randomized controlled trials (RCTs). This evidence concerns the gene IL2 and neoplasm.